Amgen

Open: 277.83 Close: 275.18 Change: -2.65

You don't have time to read all about Amgen Stock. An AI summarizes all the information for you.

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, David, Reese, Inc, Chief, Officer, Bradner, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen Inc. is largely controlled by institutional shareholders who own 78% of the company. Jay Bradner succeeds David Reese as Executive VP of Research and Development, and Chief Scientific Officer. FDA Grants Priority Review to Amgens Tarlatamab Application for Advanced Small Cell Lung Cancer.

Today's News

Amgen Inc. is largely controlled by institutional shareholders who own 78% of the company. The general public, who are usually individual investors, hold a 22% stake in Amgen. Amgen is an Equal Opportunity Employer and will consider all qualified applicants for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, or disability status. The ABE website will be down for maintenance on Friday, 22 December. US equity markets close higher Thursday after a decline in jobless claims and a surprise increase in retail sales. Financial giants have made a conspicuous bearish move on Amgen. David Reese is stepping into the future as EVP and Chief Technology Officer at Amgen. He is handing the R&D reigns over to Jay Bradner. David Reese, M.D., joins Amgen as Executive Vice President, Chief Technology Officer at Amgen. Jay Bradner succeeds David Reese as Executive VP of Research and Development, and Chief Scientific Officer. Amgen remembers Chris Van Den Broucke, who passed away from cancer. #mycompany #brandstorytelling: Happy Mothers Day! Amgen Inc. - Consensus ‘buy rating and.9% upside potential. Amgen inc. - consensus buy rating. Amgen stock price | amgn stock quote, news, and history | markets insider. Amgen Stock Price | AMGN Stock Quote, News, and History | Markets Insider Menu icon. In the Aftermath of Amgen v. Sanofi, Federal Circuit Finds Functional Antibody Claims Invalid for Lack of enablement. Amgen Inc. competitive intelligence manager, oncology/gen med/inflammation jobs at amgen in thousand oaks. How will you put your skills, experience and passion to work toward your goals? Amgen announced two changes to its senior leadership team in the areas of research and development and technology. FDA Grants Priority Review to Amgens Tarlatamab Application for Advanced Small Cell Lung Cancer. Federal Trade Commission today finalized a consent order that resolves potential competitive harm stemming from Amgen Inc.s acquisition of Horizon Therapeutics plc. The FTC sued to block the deal alleging that the acquisition would enable Amgen to leverage its large portfolio of blockbuster drugs to pressure insurance companies and pharmacy benefit managers. Amgen announces two changes to its senior leadership team in the research and development areas. Horizon Therapeutics (HZNP) stock is sinking after the FTC reportedly decided to sue to block its merger. James Bradner will be responsible for advancing Amgens pipeline of potential first-in-class medicines in all stages of development. David M. Reese joined Amgen in 2005 and has led the R&D organization since 2018.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, David, Reese, Inc, Chief, Officer, Bradner, and the most common words in the summary are: amgen, stock, inc, market, comment, report, news, . One of the sentences in the summary was: Amgen Inc. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #inc #market #comment #report #news.